BU-32

BU-32 is a novel small molecule proteasome inhibitor developed for the treatment of multiple myeloma and various solid tumors. It was synthesized and characterized by researchers at the University of Texas Health Science Center at San Antonio. BU-32 functions by potently inhibiting the chymotryptic- and caspase-like activities of the 26S proteasome, leading to the downregulation of inflammatory and angiogenic markers and the induction of apoptosis in cancer cells. In preclinical studies, it has demonstrated significant efficacy in multiple myeloma models, including the reduction of osteolytic bone lesions, and has shown activity against pancreatic, ovarian, and prostate cancer cell lines.